Looking back at an EPAD-tastic 2016!

Another EPAD year has passed and we are proud to look back at a lot of successful deliveries and established relationships and look forward to 2017. To celebrate turning two, we list herein some of our key achievements of the past 12 months. January At the turn of the year, we welcomed the 36th EPAD…

EPAD welcomes new partner Roche

We are pleased to announce the arrival of a new project partner, Roche. We say a warm welcome to Roche and look forward to our collaboration. The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European…

EPAD turns two!

With the beginning of this new year, the EPAD project is celebrating it’s 2nd birthday. 2016 was truly exceptional, with the start of the EPAD LCS (longitudinal cohort study) being the highlight of the year. we are looking forward to doing even better this year! Wishing you all an exciting and happy New Year, The…

Our sister project AMYPAD presents at two international conferences

Our sister project, Amyloid imaging to prevent Alzheimer’s disease (AMYPAD), which began its activities on 1 October 2016, has recently been invited to two international conferences. Members of the project consortium gave two poster presentations, at the following events: The Lancet Neurology Conference “Preclinical neurodegenerative disease: towards prevention and early diagnosis”, London 19-21 October 2016.…

EPAD gets a mention in the Financial Times

On 13 December 2016, the Financial Times (FT) published a letter to the Editor, from EPAD Executive Committee member Dr Jose Luis Molinuevo of the BarcelonaBeta Brain Research Center. The letter was titled “Early intervention is key to tackling Alzheimer’s”. Making reference to the FT editorial “The case for prioritising Alzheimer’s research” of 26 November…

EPAD invited to speak at EU Presidency conference

On 29 November, the Slovak Presidency of the European Union organised a conference on “ Alzheimer’s disease – epidemic of the third millennium: Are we ready to face it?” in Bratislava, focussing on four key themes discussed by four panels. One of the panels was on “Prevention and Intervention strategies in Alzheimer’s disease” and included…

EPAD paper reviews effects of disclosing AD biomarker results to healthy individuals

Current Alzheimer’s disease (AD) research initiatives focus on cognitively healthy individuals with biomarkers that are associated with the development of AD. It is unclear whether biomarker results should be returned to research participants and what the psychological, behavioural and social effects of disclosure are. A systematic review by the European Prevention of Alzheimer’s Dementia (EPAD)…

EPAD conference held in Switzerland

On 10 November 2016, the European Prevention of Alzheimer’s Dementia (EPAD) initiative held a public conference in Geneva, Switzerland, in collaboration with Hôpitaux universitaires de Genève (HUG). Approximately 100 delegates attended the French and English-language conference, “Prévenir la maladie d’Alzheimer en Suisse – Un but atteignable“ (Preventing Alzheimer’s disease in Switzerland – A realistic goal).…

Interview with Karen Ritchie

What is your current role in EPAD? I am co-chair with Michael Ropacki of the Clinical and Cognitive Outcomes Scientific Advisory Group (CCO-SAG), which is part of WP1. I am also a member of the Epidemiology Advisory Group. The CCO-SAG includes leading neuropsychologists and neurologists from Europe and the USA, and our work has principally…